Cargando…

Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision

AIM: To compute the uncertainty of time‐in‐ranges, such as time in range (TIR), time in tight range (TITR), time below range (TBR) and time above range (TAR), to evaluate glucose control and to determine the minimum duration of a trial to achieve the desired precision. MATERIALS AND METHODS: Four fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Camerlingo, Nunzio, Vettoretti, Martina, Sparacino, Giovanni, Facchinetti, Andrea, Mader, Julia K., Choudhary, Pratik, Del Favero, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518626/
https://www.ncbi.nlm.nih.gov/pubmed/34212483
http://dx.doi.org/10.1111/dom.14483
_version_ 1784584267977719808
author Camerlingo, Nunzio
Vettoretti, Martina
Sparacino, Giovanni
Facchinetti, Andrea
Mader, Julia K.
Choudhary, Pratik
Del Favero, Simone
author_facet Camerlingo, Nunzio
Vettoretti, Martina
Sparacino, Giovanni
Facchinetti, Andrea
Mader, Julia K.
Choudhary, Pratik
Del Favero, Simone
author_sort Camerlingo, Nunzio
collection PubMed
description AIM: To compute the uncertainty of time‐in‐ranges, such as time in range (TIR), time in tight range (TITR), time below range (TBR) and time above range (TAR), to evaluate glucose control and to determine the minimum duration of a trial to achieve the desired precision. MATERIALS AND METHODS: Four formulas for the aforementioned time‐in‐ranges were obtained by estimating the equation's parameters on a training set extracted from study A (226 subjects, ~180 days, 5‐minute Dexcom G4 Platinum sensor). The formulas were then validated on the remaining data. We also illustrate how to adjust the parameters for sensors with different sampling rates. Finally, we used study B (45 subjects, ~365 days, 15‐minute Abbott Freestyle Libre sensor) to further validate our results. RESULTS: Our approach was effective in predicting the uncertainty when time‐in‐ranges are estimated using n days of continuous glucose monitoring (CGM), matching the variability observed in the data. As an example, monitoring a population with TIR = 70%, TITR = 50%, TBR = 5% and TAR = 25% for 30 days warrants a precision of ±3.50%, ±3.68%, ±1.33% and ±3.66%, respectively. CONCLUSIONS: The presented approach can be used to both compute the uncertainty of time‐in‐ranges and determine the minimum duration of a trial to achieve the desired precision. An online tool to facilitate its implementation is made freely available to the clinical investigator.
format Online
Article
Text
id pubmed-8518626
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-85186262021-10-21 Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision Camerlingo, Nunzio Vettoretti, Martina Sparacino, Giovanni Facchinetti, Andrea Mader, Julia K. Choudhary, Pratik Del Favero, Simone Diabetes Obes Metab Original Articles AIM: To compute the uncertainty of time‐in‐ranges, such as time in range (TIR), time in tight range (TITR), time below range (TBR) and time above range (TAR), to evaluate glucose control and to determine the minimum duration of a trial to achieve the desired precision. MATERIALS AND METHODS: Four formulas for the aforementioned time‐in‐ranges were obtained by estimating the equation's parameters on a training set extracted from study A (226 subjects, ~180 days, 5‐minute Dexcom G4 Platinum sensor). The formulas were then validated on the remaining data. We also illustrate how to adjust the parameters for sensors with different sampling rates. Finally, we used study B (45 subjects, ~365 days, 15‐minute Abbott Freestyle Libre sensor) to further validate our results. RESULTS: Our approach was effective in predicting the uncertainty when time‐in‐ranges are estimated using n days of continuous glucose monitoring (CGM), matching the variability observed in the data. As an example, monitoring a population with TIR = 70%, TITR = 50%, TBR = 5% and TAR = 25% for 30 days warrants a precision of ±3.50%, ±3.68%, ±1.33% and ±3.66%, respectively. CONCLUSIONS: The presented approach can be used to both compute the uncertainty of time‐in‐ranges and determine the minimum duration of a trial to achieve the desired precision. An online tool to facilitate its implementation is made freely available to the clinical investigator. Blackwell Publishing Ltd 2021-07-21 2021-11 /pmc/articles/PMC8518626/ /pubmed/34212483 http://dx.doi.org/10.1111/dom.14483 Text en © 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Camerlingo, Nunzio
Vettoretti, Martina
Sparacino, Giovanni
Facchinetti, Andrea
Mader, Julia K.
Choudhary, Pratik
Del Favero, Simone
Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
title Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
title_full Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
title_fullStr Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
title_full_unstemmed Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
title_short Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
title_sort design of clinical trials to assess diabetes treatment: minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518626/
https://www.ncbi.nlm.nih.gov/pubmed/34212483
http://dx.doi.org/10.1111/dom.14483
work_keys_str_mv AT camerlingonunzio designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT vettorettimartina designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT sparacinogiovanni designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT facchinettiandrea designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT maderjuliak designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT choudharypratik designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT delfaverosimone designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision
AT designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision